Ospedale Pediatrico Bambino Gesù is a tertiary care academic children's hospital located in Rome that is under extraterritorial jurisdiction of the Holy See. As a tertiary children referral centre, the hospital provides over 20 specialties of healthcare through 10 pediatric departments.

There are 607 beds in Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica Ospedale Pediatrico Bambino Gesu - IRCCS.

During the past decade, Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica Ospedale Pediatrico Bambino Gesu - IRCCS conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 1 clinical trials were completed, i.e. on average, 20% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 1 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica Ospedale Pediatrico Bambino Gesu - IRCCS" #1 collaborator was "CRISPR Therapeutics" with 3 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica Ospedale Pediatrico Bambino Gesu - IRCCS" are "Hemoglobinopathies" (3 trials), "Sickle Cell Disease" (3 trials), "Hematological Diseases" (2 trials), "Beta-Thalassemia" (1 trials) and "Genetic Diseases, Inborn" (1 trials). Many other conditions were trialed in "Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica Ospedale Pediatrico Bambino Gesu - IRCCS" in a lesser frequency.

Most popular intervention types in "Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica Ospedale Pediatrico Bambino Gesu - IRCCS" are "Biological" (3 trials) and "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "CTX001" (3 trials), "Atezolizumab" (2 trials), "Alectinib" (1 trials), "Belvarafenib" (1 trials) and "Entrectinib" (1 trials). Other intervention names were less common.

The vast majority of trials in "Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica Ospedale Pediatrico Bambino Gesu - IRCCS" are 5 trials for "All" genders.

Currently, there are NaN active trials in "Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica Ospedale Pediatrico Bambino Gesu - IRCCS". undefined are not yet recruiting, 2 are recruiting, 1 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were undefined completed trials in Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica Ospedale Pediatrico Bambino Gesu - IRCCS, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica Ospedale Pediatrico Bambino Gesu - IRCCS, 1 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".